Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) reported Q4 2016 results in September 2016 with $-0.34/Share earnings per share or EPS. The analysts, on the contrary, had estimated the EPS to be $-0.2/Share, which led to a difference in earnings by $-0.14. The company has managed to surprise everyone with -70% in its earnings for the fourth quarter of 2016. What would be the current quarter earnings? Will Arrowhead Pharmaceuticals take everyone on the surprising stride yet again? Let us find out what analysts have to say about it.
What analysts believe about company’s Q12017?
The companies are given recommendations from 1 to 5, depicting strong buy to strong sell (where 1 represents strong buy and 5 represents strong sell). With the company announcing its price target of $1.8 for the one year, the analysts reached a consensus of a 3 rating for Arrowhead Pharmaceuticals.
For the coming quarter, when this company will report its Q12017 financial results, it would be interesting to see how far the analysts could predict its EPS. As of now, two of these analysts are speculating $-0.09/share EPS. As far as its one year EPS is concerned, five of the analysts have predicted median target 2.00.
Potential to earn $19.84 Million revenue for Q12017
As far as the revenue estimate is concerned, a few analysts believe that the company can report a growth graph with $19.84 Million average revenue for Q12017. There has been a lot of buzz around the high and low revenue predictions as well. Among various analysts predicting the revenue of Arrowhead Pharmaceuticals, the high revenue prediction is settled for 35.3 Million, while the least revenue that this company is expected to get is 4.38 Million.
The analysts’ views, ratings and revenue predictions give an insight to what the first quarter of the New Year would be like for this company. No matter what, the experts are counting on this company to illustrate a long term growth rate of 0.0733.
